2026 Crowdfunding Campaign
CROWFUNDING ROUND OPENING SOON
Help 2.8 million dialysis patients regain their lives.
The groundbreaking Neokidney™ portable hemodialysis device will be launched in 2027. This device will give back autonomy and quality of live to many kidney patients all over the world. Nextkidney will be the first to make portable hemodialysis available to patients. Next up : Through Invesdor, you'll soon have one last chance to invest in the Dutch company Nextkidney BV before its commercial launch.
- From 275 Euros, you can take part
No commitment. Pre-registered supporters receive the information and the link before the round is announced publicly.
WHY NEXTKIDNEY
Dialysis to better fit in normal life.
For 2.8 million people living with kidney failure, dialysis is not only a lifesaving treatment. It is a rhythm that defines everyday life : hospital appointments, travel limits, schedules, low energy levels and constant planning around care.
Neokidney is a portable home hemodialysis device in the process of CE marking. It combines compact patented technology (10kg) with a much lower need for dialysis fluid (5ltr.) and a unique plug and play concept as its needs no special infrastructure at all. With the Neokidney system finally, treatment adapts to the patient instead of the other way around.
WHY NOW
A decade of progress, step by step.
Since 2014, every year has brought Neokidney closer to patients : engineering, testing, manufacturing, recent clinical trial results and currently regulatory progress towards CE approval and FDA clearance. What remains is certification and the preparation for market introduction.
RAISED SINCE THE LAST CROWFUNDING ROUND
€40.1M
Series B, EIC Accelerator and European Investment Bank
CLINICAL TREATMENTS SUCCESSFULLY PERFORMED
500+
By dialysis nurses in medical centres in NL, BE and FR
PATIENTS IN EU CLINICAL TRIALS
29
Studies running at UMC's in Utrecht, Leiden, Brussels and Caen
Insurer backing, technical standards, NEN Innovation Award, Series B2014 to 2022
Foundation
Key step toward CE markingJUN 2023
ISO 13485 certified
In a Series B equity roundDEC 2023
€22.6M raised
First in human tests in Singapore and FranceJUL 2024
First human trials
Pilot line brings sorbent production in house, lowering cost and supplier dependenceJUL 2024
€3M government grant
ALCER patient award for renal care innovationNOV 2024
Patient Innovation Award
European Accelerator award (EICA) and EIB Investment €17.5MJUL 2025
European Innovation Award
In 4 European clinical centres start to treat 25 patients in 500 treatmentsJAN 2026
EU clinical trials start
Treatments performed successfully and ready to progress towards in-home studySEP 2026
500+ treatments
CE and FDA pathways, scaling production capacity, market introductionWHAT COMES NEXT
Certification and launch
NEW
Prof. Dr. med. Dieter Bach joins as Chief Medical Officer
Strengthening the clinical leadership team.
Internationally recognized nephrologist and home hemodialysis expert with over 30 years of experience in kidney care and dialysis innovation. Previously served as Chairmen of KfH, Germany’s largest kidney care and dialysis organization.
As CMO of Nextkidney, he leads the clinical and medical strategy behind the Neokidney, helping ensure the device delivers safe, effective, and patient-centered treatment while supporting its adoption in clinical practice.
THREEFOLD VALUE
Why this matters, on three levels.
01 Quality of life
More freedom for patients while enabling health gain by more frequent and friendlier treatment.
More control over the week, mobility with treatment fitting easy into regular daily live of people who depend on dialysis. The Neokidney device is designed for ease of use to enable patients to take their treatment whenever, wherever they need.
02 Healthcare system
Less pressure on care
Reduced healthcare costs and pressure on scarce medical staff and dialysis capacity.
03 Investors
Participation on equal terms
This investment round opens soon, and crowd investors can take part through Invesdor on the same terms as the current professional investors. It is the last opportunity to invest before the commercial launch.
SOCIAL PROOF
Healthcare insurers, Nephrologists and Patients believe in the Neokidney
Prof. Dr. Marcel Levi
Kidney patient, Jenneke Bresser
KNOW FIRST, DECIDE LATER
Pre-registered supporters go first.
When the round opens, pre-registered supporters receive the information and the link before it is announced publicly. Pre-registration does not oblige you to invest.
- Early notification the moment the round opens
- A direct link to the official Invesdor page
- Key information as soon as it is public
- Updates on the next steps in our journey
EARLY ACCESS OPENS IN
Pre-registered supporters receive the link first.
When the countdown ends you get a direct link to the official Invesdor page.
SUPPORTED BY AND IN COLLABORATION WITH
PRE-REGISTRATION
Be among the first to hear when the round opens.
Leave your details and we will send you the information and the link as soon as the round opens on Invesdor.
By submitting this form you agree that Nextkidney may contact you by email about the upcoming crowdfunding round and related company updates. You can unsubscribe at any time.